COMPOSITIONS AND METHODS FOR ENHANCING TRANSPORT THROUGH MUCUS
The invention generally relates to compositions and methods for transporting substances across mucosal barriers. The invention also relates to methods of making and using such substances.
1 - 76 . (canceled)
77 . A method for diagnosing a condition in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising
(a) a plurality of particles, each particle comprising:
(i) a pharmaceutically acceptable polymer core, selected from the group consisting of poly(lactic-co-glycolic) acid (PLGA), poly(D,L-lactic-co-glycolic) acid), polyethylenimine, dioleyltrimethyammoniumpropane/dioleyl-sn-glycerolphosphoethanolamine, and polysebacic anhydride; and
(ii) a poly(ethylene glycol) (PEG) having a molecular weight of about 300 Da, about 600 Da, or about 1 kDa disposed on the outer surface of the polymer core by covalent linkage at a density of greater than 0.01 units/nm 2 ,
wherein the particle has a particle size between 150 nm and 750 nm in diameter;
(b) an imaging agent, wherein the imaging agent is
(i) disposed on or coated on the surface of the pharmaceutically acceptable polymer core or the PEG; or
(ii) covalently attached to the pharmaceutically acceptable polymer core or the PEG; and
(c) one or more pharmaceutically acceptable excipients or carriers;
wherein the pharmaceutical composition crosses a mucosal barrier.
78 . The method of claim 77 , wherein the PEG is disposed on the pharmaceutically acceptable polymer core at a density of 1 unit/nm 2 .
79 . The method of claim 77 , wherein the imaging agent is disposed on or coated on the surface of the pharmaceutically acceptable polymer core or the PEG.
80 . The method of claim 77 , wherein the imaging agent is covalently attached to the pharmaceutically acceptable polymer core or the PEG.
81 . The method of claim 77 , wherein the pharmaceutically acceptable polymer is a biodegradable pharmaceutically acceptable polymer
82 . The method of claim 77 , wherein the particle has a zeta potential of between −10 mV and 10 mV, between −10 mV and 5 mV, between −5 mV and 5 mV, or between −2 mV and 2 mV.
83 . The method of claim 77 , whereby the particle moves in human cervicovaginal mucus at a diffusivity of more than 4×10 −2 μm 2 /s at a time scale of 1 s.
84 . The method of claim 77 , wherein the imaging agent is hydrophobic, comprises hydrogen bond donors or acceptors, or is charged.
85 . The method of claim 77 , wherein the PEG has a molecular weight of about 1 kDa.
86 . The method of claim 77 , wherein the biodegradable pharmaceutically acceptable polymer hydrophobic, comprises one or more hydrogen bond donors or acceptors, or is charged.
87 . The method of claim 77 , wherein the biodegradable pharmaceutically acceptable polymer is a poly(D,L-lactic-co-glycolic) acid.
88 . The method of claim 77 , wherein the mass of the PEG makes up at least 1/3400, 1/2000, 1/1000, 1/500, 1/200, 1/100, 1/50, 1/20, 1/5, 1/2, or 9/10 of the mass of the particle.
89 . The method of claim 77 , wherein the radioactive agent is a radioactive heavy metal, a radioactive chelate, 43 K, 52 Fe, 57 Co, 67 Cu, 67 Ga, 68 Ga, 123 I, 125 I, 131 I, 132 I, or 99 Tc.
90 . A method of delivering a radioactive agent to a tissue, comprising administering to a patient a pharmaceutical composition comprising
(a) a plurality of particles, each particle comprising:
(i) a pharmaceutically acceptable polymer core, selected from the group consisting of poly(lactic-co-glycolic) acid (PLGA), poly(D,L-lactic-co-glycolic) acid), polyethylenimine, dioleyltrimethyammoniumpropane/dioleyl-sn-glycerolphosphoethanolamine, and polysebacic anhydride; and
(ii) a poly(ethylene glycol) (PEG) having a molecular weight of about 300 Da, about 600 Da, or about 1 kDa disposed on the outer surface of the polymer core by covalent linkage at a density of greater than 0.01 units/nm 2 ,
wherein the particle has a particle size between 150 nm and 750 nm in diameter;
(b) a radioactive agent
(i) disposed on or coated on the surface of the pharmaceutically acceptable polymer core or the PEG; or
(ii) covalently attached to the pharmaceutically acceptable polymer core or the PEG; and
(c) one or more pharmaceutically acceptable excipients or carriers;
wherein the pharmaceutical composition crosses a mucosal barrier to delivery the radioactive agent to the tissue.
91 . The method of claim 90 , wherein the pharmaceutically acceptable polymer is a biodegradable pharmaceutically acceptable polymer
92 . The method of claim 90 , whereby the particle moves in human cervicovaginal mucus at a diffusivity of more than 4×10 −2 m 2 /s at a time scale of 1 s.
93 . The method of claim 90 , wherein the PEG has a molecular weight of about 1 kDa.
94 . The method of claim 90 , wherein the biodegradable pharmaceutically acceptable polymer is a poly(D,L-lactic-co-glycolic) acid.
95 . The method of claim 90 , wherein the mass of the PEG makes up at least 1/3400, 1/2000, 1/1000, 1/500, 1/200, 1/100, 1/50, 1/20, 1/5, 1/2, or 9/10 of the mass of the particle.
96 . The method of claim 90 , wherein the radioactive agent is a radioactive heavy metal, a radioactive chelate, 43 K, 52 Fe, 57 Co, 67 Cu, 67 Ga, 68 Ga, 123 I, 125 I, 131 I, 132 I, or 99 Tc.